Cold agglutinin disease
MONDO:0018922Cold agglutinin disease is a type of autoimmune hemolytic anemia defined by the presence of cold autoantibodies (autoantibodies which are active at temperatures below 30B0C).
Also known as: CAD, CAS, chronic cold agglutinin disease, cold agglutinin syndrome, anemia, hemolytic, cold antibody, cold antibody disease, cold antibody hemolytic anaemia, cold antibody hemolytic anemia
58 clinical trials for this condition and its sub-types, 14 tagged with Cold agglutinin disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New cell therapy offers hope for tough anemia cases
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after at least three prior treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the anemia. The …
Phase 1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental cell therapy takes on tough blood disorder
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called YTS109 in 13 adults with autoimmune hemolytic anemia that has not responded to at least three prior treatments. The therapy uses specially engineered immune cells to target and control the disease. The main goals are to check…
Phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
CAR-T therapy takes on tough blood disorder in early trial
Disease control Not yet recruitingThis early-stage trial tests a new CAR-T cell therapy called inaticabtagene autoleucel for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. The study will enroll 12 adults and primarily check for safety and the right dose.…
Phase 1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare blood disorder: linprixel trial launches
Disease control Not yet recruitingThis phase 2 trial tests linprixel, a daily pill, in 22 adults with relapsed or refractory autoimmune hemolytic anemia (AIHA). The study aims to see if the drug can improve red blood cell counts after 12 weeks. Participants start at 40mg daily, with possible dose increases if nee…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:46 UTC